JAZZ

+ Watchlist + Portfolio

Jazz Pharmaceuticals plc

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $252.16
52-Week Range: $118.19 – $265.05
Market Cap: $16.14B
P/E (TTM): 17.03
EPS (TTM): 14.60
Dividend Yield: —

Advanced Metrics

Price/Book: 3.36
PEG Ratio: 0.96
Return on Equity: 22.11%
Return on Assets: 6.86%
Gross Margin: 91.35%
Operating Margin: 26.91%
Profit Margin: 20.45%
Current Ratio: 1.78
Debt/Equity: 0.92
Total Debt: $4.41B
Free Cash Flow: $1.43B
Revenue Growth: 15.50%
Earnings Growth: —
Enterprise Value: $18.58B

JAZZ Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$3.66B	$3.83B	$4.07B	$4.27B
Cost of Revenue	$540.52M	$435.58M	$445.71M	$503.30M
Gross Profit	$3.12B	$3.40B	$3.62B	$3.76B
Research & Development	$590.45M	$849.66M	$884.00M	$782.74M
Selling, General & Admin	$1.42B	$1.34B	$1.39B	$1.81B
Operating Expenses	$2.61B	$2.80B	$2.90B	$3.25B
Operating Income	$512.27M	$597.58M	$726.63M	$517.62M
EBITDA	$544.93M	$1.23B	$1.37B	$263.49M
Pretax Income	-$372.78M	$297.93M	$470.35M	-$627.86M
Income Tax	-$158.65M	-$119.91M	-$91.43M	-$272.44M
Net Income	-$224.06M	$414.83M	$560.12M	-$356.15M
Diluted EPS	-3.58	6.10	8.65	-5.84
Diluted Shares	62.54M	72.07M	66.01M	60.98M

JAZZ Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$881.48M	$1.51B	$2.41B	$1.39B
Receivables	$651.49M	$705.79M	$716.76M	$830.75M
Inventory	$714.06M	$597.04M	$480.44M	$416.96M
Current Assets	$2.61B	$3.44B	$4.63B	$4.17B
Total Assets	$10.84B	$11.39B	$12.01B	$11.66B
Current Liabilities	$933.19M	$1.54B	$1.04B	$2.24B
Long-Term Debt	$5.69B	$5.11B	$6.08B	$4.33B
Total Debt	$5.81B	$5.79B	$6.16B	$5.42B
Total Liabilities	$7.75B	$7.66B	$7.92B	$7.34B
Retained Earnings	$733.59M	$878.66M	$1.13B	$646.18M
Shareholders' Equity	$3.09B	$3.74B	$4.09B	$4.32B
Working Capital	$1.67B	$1.90B	$3.59B	$1.92B
Net Debt	$4.84B	$4.21B	$3.70B	$3.97B

JAZZ Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$1.27B	$1.09B	$1.40B	$1.36B
Capital Expenditure	-$498.19M	-$42.96M	-$48.07M	-$209.75M
Free Cash Flow	$773.78M	$1.05B	$1.35B	$1.15B
Depreciation & Amortisation	$629.47M	$638.70M	$660.07M	$696.30M
Stock-Based Compensation	$222.00M	$226.84M	$248.04M	$291.13M
Investing Cash Flow	-$446.23M	-$163.06M	-$508.19M	-$1.51B
Financing Cash Flow	-$529.49M	-$305.25M	$20.52M	-$873.38M
Share Repurchases	-$54.00K	-$269.76M	-$311.43M	-$125.02M
Net Change in Cash	$296.26M	$623.69M	$908.23M	-$1.03B

JAZZ Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$1.05B	$1.13B	$1.20B	$1.07B	$1.21B
Cost of Revenue	$116.30M	$128.88M	$153.53M	$134.10M	$116.40M
Gross Profit	$929.40M	$997.23M	$1.04B	$934.80M	$1.09B
Research & Development	$189.90M	$198.20M	$213.91M	$196.00M	$207.50M
Selling, General & Admin	$358.40M	$530.65M	$406.21M	$352.70M	$389.20M
Operating Expenses	$710.40M	$897.22M	$789.86M	$598.20M	$766.70M
Operating Income	$219.00M	$100.01M	$254.53M	$336.60M	$325.20M
EBITDA	-$514.20M	$235.94M	$433.05M	$520.50M	$427.20M
Pretax Income	-$735.60M	$9.04M	$208.47M	$299.20M	$211.00M
Income Tax	-$17.20M	-$242.42M	$4.96M	$6.10M	$18.10M
Net Income	-$718.50M	$251.41M	$203.45M	$293.10M	$192.80M
Diluted EPS	-11.74	4.08	3.21	4.43	2.78
Diluted Shares	61.20M	61.61M	63.43M	66.10M	69.40M

JAZZ Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$1.19B	$1.33B	$1.39B	$1.84B	$1.62B
Receivables	$714.00M	$764.36M	$830.75M	$836.30M	$880.90M
Inventory	$504.99M	$483.11M	$416.96M	$437.50M	$443.00M
Current Assets	$3.35B	$3.76B	$4.17B	$4.58B	$3.97B
Total Assets	$10.94B	$11.36B	$11.66B	$11.86B	$11.08B
Current Liabilities	$2.07B	$2.27B	$2.24B	$2.25B	$2.23B
Long-Term Debt	$4.34B	$4.33B	$4.33B	$4.32B	$3.33B
Total Debt	$5.43B	$5.43B	$5.42B	$5.42B	$4.41B
Total Liabilities	$7.24B	$7.40B	$7.34B	$7.33B	$6.28B
Retained Earnings	$191.31M	$442.73M	$646.18M	$939.20M	$1.13B
Shareholders' Equity	$3.71B	$3.96B	$4.32B	$4.53B	$4.80B
Working Capital	$1.28B	$1.48B	$1.92B	$2.34B	$1.74B
Net Debt	$4.17B	$4.04B	$3.97B	$3.51B	$2.73B

JAZZ Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$88.80M	$474.65M	$362.52M	$408.20M	$415.70M
Capital Expenditure	-$12.90M	-$87.72M	-$70.23M	-$19.70M	-$172.30M
Free Cash Flow	$75.90M	$386.93M	$292.29M	$388.50M	$243.40M
Depreciation & Amortisation	$174.00M	$178.33M	$179.17M	$181.40M	$179.10M
Stock-Based Compensation	$64.50M	$88.08M	$70.85M	$74.50M	$73.30M
Investing Cash Flow	-$641.00M	-$327.75M	-$372.16M	$123.10M	$354.90M
Financing Cash Flow	-$124.40M	-$10.92M	$75.44M	-$78.50M	-$994.50M
Share Repurchases	—	-$23.00K	$0.00	—	—
Net Change in Cash	-$676.60M	$135.98M	$65.80M	$452.80M	-$223.90M

Market Snapshot

About

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases with significant unmet medical needs, particularly in neuroscience and oncology. The company is best known for Xyrem and Xywav, treatments for narcolepsy and idiopathic hypersomnia, which generate substantial revenue. Jazz markets Epidiolex for seizures associated with rare forms of epilepsy and Zepzelca for small cell lung cancer. The company maintains a robust pipeline of late-stage development programs and pursues strategic acquisitions to expand its portfolio.